科兴制药：人干扰素α1b吸入溶液纳入突破性治疗品种名单

Core Viewpoint - The announcement highlights that the inhalation solution of human interferon α1b, developed by the wholly-owned subsidiary of the company, has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] Group 1: Product Development - The inhalation solution is intended for the treatment of pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis [1] - As of the date of the announcement, the human interferon α1b inhalation solution is in the Phase III clinical trial stage [1] Group 2: Company Actions - The company will actively promote the research and development project and fulfill its information disclosure obligations in a timely manner [1]